



Patient : Kardashian, Kimberly
Clinic : Grady Memorial Hospital, Atlanta, GA
Gender : Female
DOB : 10/21/1980

HIGH RISK

Gene	Mutation	Known Associations
MSH2	c.8C>G	Lynch-syndrome
BRCA1	c.9A>T	Breast-cancer
BRCA2	c.10G>C	Ovarian-cancer

Gene	Start	Class	Mutation	CADD
FLI1	128810478	Silent	p.L283	0.94952
DBX1	20159961	Missense	p.T122A	0.77310
GLYATL1	58943657	Silent	p.R47	0.00308
LOC401717	43660971	RNA	NULL	NA
KCNA5	5044705	Silent	p.R186	0.33389
ENSG00000218758	12247360	Missense	p.P421A	0.68785
FAM113A	2838470	Silent	p.P201	0.67177
COPG	129252282	Missense	p.A31V	0.97290
CADM2	85726504	Missense	p.N8S	0.13959
ADAM19	157491660	Missense	p.P684S	0.11456

Gene Details: *MSH2* c.8C>G : NM-000251.2

Functional Significance: Deleterious

The heterozygous germline *MSH2* c.8C>G is predicted to result in the premature truncation of the *MSH2* protein due to abnormal protein production and/or function.

Clinical Significance: High Cancer Risk

This mutation is associated with increased cancer risk and should be regarded as clinically significant.

Additional Information

Genes Analyzed: *APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD51C, SMAD4, STK11, TP53*



Disclaimer: The technical specifications summary of ICRC Gene Expose describes the analysis, method, performance, nomenclature, and interpretive criteria of this test. The classification and interpretation of variants identified reflect the current state of scientific understanding at the time of this report.